MIRON-ACUTE: Acute Clinical Outcomes of Hemorrhagic Myocardial Infarction
Sponsor
Rohan Dharmakumar (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06110351
Collaborator
(none)
100,000
3
Study Details
Study Description
Brief Summary
Acute clinical outcomes 1. Mortality 2. Arrhythmia 3. Readmission 4. CVA 5. ADHF
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Study Design
Study Type:
Observational
Anticipated Enrollment
:
100000 participants
Observational Model:
Cohort
Time Perspective:
Retrospective
Official Title:
Acute Clinical Outcomes of Hemorrhagic Myocardial Infarction
Anticipated Study Start Date
:
Nov 1, 2023
Anticipated Primary Completion Date
:
Jan 31, 2024
Anticipated Study Completion Date
:
Jan 31, 2024
Outcome Measures
Primary Outcome Measures
- Mortality [30-days and 6 months]
Prevalence of acute mortality
Secondary Outcome Measures
- Acute heart failure [30-days and 6 months]
Prevalence of acute heart failure
- Arrhythmia [30-days and 6 months]
Prevalence of acute arrhythmia
Eligibility Criteria
Criteria
Ages Eligible for Study:
18 Years
to 85 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
-
18-85 years of age
-
Primary PCI
-
Post-PCI cardiac biomarker labs
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Rohan Dharmakumar
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
Rohan Dharmakumar,
Executive Director, Krannert Cardiovascular Research Center,
Indiana University School of Medicine
ClinicalTrials.gov Identifier:
NCT06110351
Other Study ID Numbers:
- 19978
First Posted:
Oct 31, 2023
Last Update Posted:
Nov 7, 2023
Last Verified:
Nov 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms: